September 25, 2020

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): vaccines

• [Pre-print, not peer reviewed] A one-dose vaccine candidate was shown to have an acceptable safety profile and demonstrated immunogenicity. These results come from a multi-center phase 1/2a randomized, double-blinded, placebo-controlled clinical study of the Ad26.COV2.S vaccine candidate. The vaccine platform utilizes Janssen Pharmaceutical’s replication incompetent adenovirus serotype 26 (Ad26) 54 vector and includes a stabilized SARS-CoV-2 Spike (S) protein insert. The Ad26.COV2.S is the only one-dose vaccine currently entering Phase III clinical trials in the US.

Sadoff et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. Pre-print downloaded Sept 25 from https://doi.org/10.1101/2020.09.23.20199604